GlaxoSmithKline PLC — Board/Management Information 2021

Mar 17, 2021

National Storage Mechanism | Additional information

RNS Number : 6312S

GlaxoSmithKline PLC

17 March 2021

GlaxoSmithKline plc

(the 'Company')

Chair of Audit & Risk Committee

Mr Charlie Bancroft succeeded Ms Judy Lewent as chair of the Company's Audit & Risk Committee on 13 March 2021. Ms Lewent will remain a Non-Executive Director of the Company and member of the Audit & Risk Committee and the other Board committees on which she sits until the conclusion of the 2021 Annual General Meeting due to be held on Wednesday 5 May 2021.  

V A Whyte

Company Secretary

17 March 2021

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RDNJRMPTMTTBBTB